In models of HCC, inhibitors of miRNA-221 were able to promote sensitivity to TRAIL in TRAIL-resistant cells [115], an observation confirmed by Jin et al. [116] who also identified that the lncRNA CASC2 was able to sequester miRNA-221, along with miRNA-24, in order to mediate the response to TRAIL treatment. The gene discussed is CASC2; the disease is hepatocellular carcinoma.